LONDON, Oct. 5, 2017 /PRNewswire/ — Bio-Techne has been selected as a supplier of research antibodies under Lot 1: Antibodies of the Southern Universities Purchasing Consortium (SUPC), Antibodies and Sera Framework Agreement for the United Kingdom (UK) Higher Education Sector.
The Framework serves 6 major UK-based academic consortia across England, Scotland and Wales and supports over 100 research centers. The Framework was designed to select the best suppliers to partner with the consortia’s member universities and public sector research organizations. As the first collaborative agreement of its kind, antibody based reagents were deemed to be a key area of laboratory research procurement. UK consortia member institutions account for an estimated £40m a year in expenditure for antibodies. The new agreement runs till June 30, 2019, with an option for SUPC to extend a further two years to 2021.
The awarded suppliers include both existing and new to market suppliers that have undergone extensive financial, legal, quality management system (e.g. ISO 9001, ISO 13485 and GMP) and other background checks. Suppliers awarded this agreement were noted by the SUPC to have strong visibility of their supply chains and are committed to continuous improvement of animal and employee welfare. Suppliers were scored in five key areas; supply chain and sustainability, quality of service, product -range of goods and services, product – compliance with specification and warranty as well as pricing.
Bio-Techne’s brands, R&D Systems and Novus Biologicals, combine over 45 years of antibody development and validation expertise, which is carried out at its manufacturing sites in the United States. With tens of thousands of citations and product reviews, Bio-Techne is proud to be one of the leading suppliers of antibodies in the industry for both the academic and biopharma markets.
“We are honored to be selected as a key supplier for the UK Higher Education Sector in this new Framework agreement. These excellent rankings validate Bio-Techne’s outstanding reputation as a premier supplier of life science research products, operating to the highest standards in the industry” commented Karen Padgett, Vice President of Bio-Techne’s Antibody Business Unit and Digital Marketing. “We are pleased and excited to provide researchers with an unrivalled selection of over 150,000 quality antibodies and access to our custom antibody production services manufactured under ISO 13845 quality standards.”
Gary Stapleton, Bio-Techne Vice President of Europe added, “This award underscores our commitment to the highest ethical and operational standards in the supply chain. We are also pleased to support researchers through our team of PhD-qualified technical support staff based in the UK and to offer rapid shipping from our European distribution hub based near London Heathrow Airport.”
As a preferred supplier of research antibodies successfully awarded under the Framework provision, Bio-Techne has been invited to an exclusive launch event on October 6, 2017 at the prestigious Life Science Building at the University of Bristol, UK.
Member institutions can now access the agreement through their institutional procurement systems. For more information, go to: https://www.supc.ac.uk/agreements-suppliers/agreements/agreement/576/
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD™’s in situ hybridization detection products — which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple® brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.
Senior Vice President